Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EA4000
- Development stage
- Phase 2
- Lead developer
- EA Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
EA4000 is an investigational oral bowel-cleansing agent being developed by EA Pharma Co., Ltd. for colon preparation prior to colonoscopy. It is currently in Phase I/II clinical development in Japan. The agent is designed to facilitate the clearance of fecal matter from the colon to ensure adequate mucosal visualization during endoscopic procedures. While its exact chemical composition is not publicly disclosed, it is categorized as an agent affecting digestive organs and likely functions as an osmotic laxative, consistent with other products in EA Pharma's gastrointestinal portfolio such as polyethylene glycol (PEG)-based solutions.
Beyond the preview
Go deeper on EA4000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EA4000.